###begin article-title 0
###xml 96 101 <span type="species:ncbi:9606">women</span>
Age-specific effects of estrogen receptors' polymorphisms on the bone traits in healthy fertile women: the BONTURNO study
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
Skeletal characteristics such as height (Ht), bone mineral density (BMD) or bone turnover markers are strongly inherited. Common variants in the genes encoding for estrogen receptor alpha (ESR1) and beta (ESR2) are proposed as candidates for influencing bone phenotypes at the population level.
###end p 3
###begin title 4
Methods
###end title 4
###begin p 5
###xml 37 42 <span type="species:ncbi:9606">women</span>
###xml 497 502 <span type="species:ncbi:9606">women</span>
We studied 641 healthy premenopausal women aged 20-50 years (yrs) participating into the BONTURNO study. Exclusion criteria were irregular cyclic menses, low trauma fracture, metabolic bone or chronic diseases. Serum C-telopeptide of type I collagen (CTX), osteocalcin (OC), and N-terminal propeptide of type I procollagen (P1NP) were measured in all enrolled subjects, who underwent to lumbar spine (LS), total hip (TH) and femoral neck (FN) BMD evaluation by DXA. Five hundred seventy Caucasian women were genotyped for ESR1 rs2234693 and rs9340799 and ESR2 rs4986938 polymorphisms.
###end p 5
###begin title 6
Results
###end title 6
###begin p 7
Although no genotype differences were found in body parameters, subjects with combined ESR1 CCGG plus ESR2 AA-AG genotype were taller than those with opposite genotype (P = 0.044). Moreover, ESR1 rs2234693 genotypes correlated with family history of osteoporosis (FHO) and hip fracture (FHF) (P < 0.01), while ESR2 AA-AC genotypes were strongly associated with FHF (OR 2.387, 95% CI 1.432-3.977; P < 0.001).
###end p 7
###begin p 8
When clustered by age, 20-30 yrs old subjects, having at least one ESR1 rs2234693 C allele presented lower LS- (P = 0.008) and TH-BMD (P = 0.047) than TT genotypes. In 41-50 yrs age, lower FN-BMD was associated with ESR2 AA (P = 0.0180) subjects than in those with the opposite genotype. ESR1 rs2234693 and rs9340799 and ESR2 rs4986938 polymorphisms did not correlate with age-adjusted values of OC, CTX and P1NP.
###end p 8
###begin title 9
Conclusion
###end title 9
###begin p 10
###xml 137 142 <span type="species:ncbi:9606">women</span>
These findings support the presence of age-specific effects of ESR1 and ESR2 polymorphisms on various skeletal traits in healthy fertile women.
###end p 10
###begin title 11
Background
###end title 11
###begin p 12
###xml 253 254 253 254 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
Bone mass increases during the growth period and peaks by young adulthood. Although the greatest gain in bone mass takes place during the accelerated growth in adolescence, bone mineral density (BMD) continues to increase for several years (yrs) later [1].
###end p 12
###begin p 13
###xml 153 154 153 154 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 290 291 290 291 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 265 270 <span type="species:ncbi:9606">women</span>
The importance of peak bone mass as a determinant of osteoporosis and fractures later in life is supported by several studies. For instance, Hui et al. [2] estimated that peak bone mass and postmenopausal bone loss contributed equally to bone status in 70-year-old women. Hernandez et al. [3] estimated that a 10% increase in peak BMD may delay the development of osteoporosis by 13 yrs.
###end p 13
###begin p 14
###xml 313 314 313 314 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 327 328 327 328 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 585 586 585 586 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 308 311 <span type="species:ncbi:9606">men</span>
###xml 320 325 <span type="species:ncbi:9606">women</span>
###xml 622 630 <span type="species:ncbi:9606">patients</span>
Low BMD is, indeed, a major determinant of osteoporotic fractures, even though environmental factors, such as dietary intake and physical activity play an important role in the BMD determination. From studies of monozygotic and dizygotic twins, inheritance was estimated to account for 60-80% of BMD in both men [4] and women [5]. Many other predictors of fragility fracture, bone turnover markers and skeletal geometry are also under genetic control. In the last two decades, an exceptionally wide range of candidate genes have been proposed as risk markers of osteoporosis outcomes [6], but our ability to predict which patients are most likely to sustain low BMD and/or osteoporotic fractures based on genetic screening is still far to be complete.
###end p 14
###begin p 15
###xml 79 83 75 79 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ESR1</italic>
###xml 95 99 88 92 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ESR2</italic>
###xml 150 151 143 144 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 188 191 181 184 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pvu</italic>
###xml 195 209 188 202 <italic xmlns:xlink="http://www.w3.org/1999/xlink">rs2234693, C/T</italic>
###xml 215 218 208 211 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Xba</italic>
###xml 221 235 214 228 <italic xmlns:xlink="http://www.w3.org/1999/xlink">rs9340799, A/G</italic>
###xml 244 249 237 242 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ESR1 </italic>
###xml 266 271 259 264 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AluI </italic>
###xml 272 286 265 279 <italic xmlns:xlink="http://www.w3.org/1999/xlink">rs4986938, A/G</italic>
###xml 320 323 313 316 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UTR</italic>
###xml 328 333 321 326 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ESR2 </italic>
###xml 594 595 587 588 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
Among the analyzed candidate genes are those encoding estrogen receptor alpha (ESR1) and beta (ESR2). In particular, single nucleotide polymorphisms [7] defined by the restriction enzymes PvuII (rs2234693, C/T) and XbaI (rs9340799, A/G) in the ESR1 intron 1, and by AluI (rs4986938, A/G) in the 3'-untraslated region (3'UTR) of ESR2 exon 8 have been evaluated in more than 90 population-based studies, with inconclusive results. For their specific ethnic distribution, clinical predictability of estrogen receptor polymorphisms are strongly dependent on the analysis of homogenous populations [8].
###end p 15
###begin p 16
###xml 234 239 234 239 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ESR1 </italic>
###xml 240 250 240 250 <italic xmlns:xlink="http://www.w3.org/1999/xlink">rs2234693 </italic>
###xml 254 263 254 263 <italic xmlns:xlink="http://www.w3.org/1999/xlink">rs9340799</italic>
###xml 269 274 269 274 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ESR2 </italic>
###xml 275 284 275 284 <italic xmlns:xlink="http://www.w3.org/1999/xlink">rs4986938</italic>
###xml 170 175 <span type="species:ncbi:9606">women</span>
The purpose of this study was to relate skeletal traits such as height (Ht), BMD and bone turnover markers, measured in a large cohort of healthy premenopausal Caucasian women aged 20-50 yrs, to several genotyped polymorphisms in the ESR1 (rs2234693 and rs9340799) and ESR2 (rs4986938) loci.
###end p 16
###begin title 17
Methods
###end title 17
###begin title 18
Subject population
###end title 18
###begin p 19
###xml 259 260 259 260 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 46 58 <span type="species:ncbi:9606">participants</span>
The analyzed population included all enrolled participants in the Bone Turnover Range of Normality (BONTURNO) study, a multicenter, multiracial/multiethnic cohort study from young adulthood to midlife. The design of the BONTURNO has been described in detail [9]. A total of 641 subjects were enrolled from 20 different centers uniformly distributed across Italy. Each center was asked to recruit four to six healthy individuals for each age range: 20-24, 25-29, 30-34, 34-39, 40-44, and 45-49. A prerequisite for the screening was the presence of regular monthly cyclic menses (cycles occurring every 25-35 days). Subjects were excluded if they had previously suffered a low trauma fracture (as judged by the investigator), any metabolic bone diseases, or chronic diseases capable to influence bone metabolism (malignancies, rheumatoid arthritis, diabetes, etc.). Subjects were also excluded if abnormal laboratory results in serum calcium, creatinine, phosphate, and magnesium were found upon screening.
###end p 19
###begin p 20
The study sites received formal approval from the local Ethics Committees and obtained signed informed consent from each subject before enrolment.
###end p 20
###begin title 21
Clinical examination
###end title 21
###begin p 22
###xml 486 491 <span type="species:ncbi:9606">women</span>
###xml 529 534 <span type="species:ncbi:9606">women</span>
The subjects considered to be eligible for inclusion in the study were asked to come to the outpatient clinic by 7:30-8:30 a.m. in fasting condition for the collection of a blood sample. Six aliquots of serum samples were separated and kept on dry ice during transportation by courier to Interlab (Munich, Germany), where they were kept at -80degreesC for the later measurements of bone turnover markers in all subjects, and of follicle stimulating hormone (FSH) and serum estradiol in women aged >39 yrs. It was preplanned that women with FSH levels >30 IU/L, despite menstruating normally, would be analyzed separately and defined as "perimenopausal".
###end p 22
###begin p 23
###xml 368 370 368 370 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 952 953 952 953 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 50 53 <span type="species:ncbi:255564">DXA</span>
###xml 197 200 <span type="species:ncbi:255564">DXA</span>
After breakfast, organized locally, a Dual X-ray (DXA) evaluation was carried out and a multi-item questionnaire administrated. Hologic (20 centers) and Lunar (3 centers) instruments were used for DXA evaluation of BMD at the lumbar spine (LS), femoral neck (FN) and total hip (TH). The values obtained with Lunar instruments were standardized to Hologic instruments [10]. The questionnaire included personal data and evaluated factors that potentially influence bone turnover, including general health and any type of continuous use of drugs (including oral contraceptives or calcium supplements), fracture history, family (i.e. first degree relative) history of low-energy fractures and/or of osteoporosis (defined by LS- and/or FN-BMD<-2.0 SDS), number of pregnancies, smoking, alcohol consumption, sunlight exposure and menstrual cycle day. In all subjects body Ht and weight were assessed (Harpender stadiometer) and the body mass index (BMI, kg/m2) was derived.
###end p 23
###begin p 24
The bone turnover markers investigated in this study were serum C-telopeptide of type I collagen (CTX), osteocalcin (OC), and N-terminal propeptide of type I procollagen (P1NP). The three bone turnover markers, FSH, and estradiol were measured by automated immunoassay with the ECLIA device from Roche Diagnostics (Palo Alto, CA, USA). The coefficients of variation (interassay) provided by Interlab ranged from 7 to 14%. Additional biochemical tests performed by local laboratories included serum calcium, creatinine, phosphate, and magnesium.
###end p 24
###begin title 25
Genotyping
###end title 25
###begin p 26
###xml 226 231 226 231 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ESR1 </italic>
###xml 235 240 235 240 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ESR2 </italic>
###xml 434 436 434 436 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
Genomic DNA was extracted from peripheral blood lymphocytes using a column microvolume system (NucleoSpin Blood Quick Pure, Macherey-Nagel, Easton, PA, USA) according to the manufacturer's instructions. Genomic DNA regions of ESR1 and ESR2 genes, containing the above described polymorphisms were analyzed by polymerase chain reactions (PCR), using specific couples of primers designed by Primer3 (v.0.4.0) program, freely available [11].
###end p 26
###begin title 27
ESR1 gene polymorpisms
###end title 27
###begin p 28
###xml 36 46 36 46 <italic xmlns:xlink="http://www.w3.org/1999/xlink">rs2234693 </italic>
###xml 50 60 50 60 <italic xmlns:xlink="http://www.w3.org/1999/xlink">rs9340799 </italic>
###xml 215 219 213 215 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#174; </sup>
###xml 590 596 550 556 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PvuII </italic>
###xml 599 604 559 564 <italic xmlns:xlink="http://www.w3.org/1999/xlink">XbaI </italic>
###xml 641 647 601 607 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PvuII </italic>
###xml 880 882 840 842 <italic xmlns:xlink="http://www.w3.org/1999/xlink">T </italic>
###xml 890 892 850 852 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C </italic>
###xml 912 917 872 877 <italic xmlns:xlink="http://www.w3.org/1999/xlink">XbaI </italic>
###xml 1150 1152 1110 1112 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A </italic>
###xml 1160 1162 1120 1122 <italic xmlns:xlink="http://www.w3.org/1999/xlink">G </italic>
Intron 1 region containing both the rs2234693 and rs9340799 polymorphisms has been amplified by PCR in a final volume of 50 mul containing 1x of reaction buffer, 0.4 muM of each primer, 0.2 mM of dNTPs, 1 U of GoTaq(R) DNA Polymerase (Promega, Madison, WI - USA) and about 50 ng of genomic DNA. Thermal cycling conditions were 94degreesC for 5 min, 35 cycles of 94degreesC for 30 sec, 60degreesC for 30 sec and 72degreesC for 1 min, followed by an additional 72degreesC for 5 min stabilization step. Two aliquots of PCR products were separately digested overnight at 37degreesC with 1 U of PvuII or XbaI (MBI Fermentas, Vilnius, Lithuania). PvuII digestion products were visualised by 3% ethidium bromide stained agarose gel electrophoresis. Fragments were separated depending on their length revealing presence or absence of the restriction site and identifying respectively the T and the C alleles. Similarly, XbaI digestion products were visualised by 3% ethidium bromide stained agarose gel electrophoresis. Fragments were separated depending on their length revealing presence or absence of the restriction site and identifying respectively the A and the G alleles.
###end p 28
###begin title 29
ESR2 gene polymorphism
###end title 29
###begin p 30
###xml 147 151 145 147 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#174; </sup>
###xml 506 511 466 471 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AluI </italic>
###xml 561 566 521 526 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AluI </italic>
###xml 799 801 759 761 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A </italic>
###xml 809 811 769 771 <italic xmlns:xlink="http://www.w3.org/1999/xlink">G </italic>
PCR amplification was performed in a final volume of 50 mul containing 1x of reaction buffer, 0.4 muM of each primer, 0.2 mM of dNTPs, 1 U of GoTaq(R) DNA Polymerase (Promega, Madison, WI - USA) and about 50 ng of genomic DNA. Thermal cycling conditions were 94degreesC for 5 min, 35 cycles of 94degreesC for 30 sec, 60degreesC for 30 sec and 72degreesC for 30 sec, followed by an additional 72degreesC for 5 min stabilization step. The 168 bp PCR product was digested over-night at 37degreesC with 1 U of AluI endonuclease (MBI Fermentas, Vilnius, Lithuania). AluI digestion products were visualised by 3% ethidium bromide stained agarose gel electrophoresis. Fragments were separated depending on their length revealing presence or absence of the restriction site and identifying respectively the A and the G alleles.
###end p 30
###begin title 31
Statistical analyses
###end title 31
###begin p 32
###xml 149 150 145 146 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 222 223 218 219 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r</italic>
###xml 322 323 318 319 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 416 418 410 412 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 541 543 535 537 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 546 548 540 542 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
Data were expressed as mean +/- standard deviation (SD) unless otherwise stated. Statistical evaluation was performed using standard Chi-squared (chi2) test, one-way analysis of variance (ANOVA) and Pearson's correlation (r) where multiple samples were obtained. When two sets of data were compared, an unpaired Student's t-test was employed. A two-tailed significance test was used for all comparisons. Standard chi2 test was also used to compare observed genotype frequencies with those expected under the Hardy-Weinberg (HW) equilibrium [12]. P < 0.05 was considered statistically significant. All analyses were performed using the SAS statistical package, version 8.2 (SAS Institute, Cary, NC).
###end p 32
###begin title 33
Results
###end title 33
###begin p 34
###xml 37 42 <span type="species:ncbi:9606">women</span>
###xml 136 141 <span type="species:ncbi:9606">women</span>
###xml 197 204 <span type="species:ncbi:9606">patient</span>
###xml 351 359 <span type="species:ncbi:9606">patients</span>
A total of 641 healthy premenopausal women meeting the inclusion and exclusion criteria were recruited from 20 investigative sites. Two women were excluded due to serum calcium >10.5 mg/dL and one patient for P1NP and OC levels three times above the upper normal range, who is now under investigation for suspected Paget disease of the bone. No other patients had abnormal values of serum phosphate, magnesium or creatinine (data not shown).
###end p 34
###begin p 35
###xml 380 381 380 381 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 35 40 <span type="species:ncbi:9606">women</span>
###xml 336 341 <span type="species:ncbi:9606">women</span>
Serum FSH >30 IU/L was found in 18 women even though menstruating normally. They are considered per protocol as perimenopausal. Twelve subjects were on treatment with stable doses of thyroxine, 11 on antihyperthensive agents not associated with diuretics, 3 on serotonin-uptake inhibitors, and 2 on proton pump inhibitors. Eighty-three women were on oral contraceptive treatment [9].
###end p 35
###begin p 36
###xml 75 80 <span type="species:ncbi:9606">women</span>
###xml 261 266 <span type="species:ncbi:9606">women</span>
Genetic data were available for 573 enrolled subjects. Three non-Caucasian women were excluded from genetic analyses and their exclusion did not modify the results of the study (data not shown). Statistical analysis was performed on the remaining 570 Caucasian women who were not on treatment with known bone-active drugs.
###end p 36
###begin p 37
###xml 92 97 92 97 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ESR1 </italic>
###xml 101 106 101 106 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ESR2 </italic>
###xml 134 135 134 135 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 151 153 151 153 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 365 370 365 370 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ESR1 </italic>
###xml 374 379 374 379 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ESR2 </italic>
###xml 496 513 496 513 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ESR1 rs2234693 CC</italic>
###xml 515 528 515 528 <italic xmlns:xlink="http://www.w3.org/1999/xlink">rs9340799 GG </italic>
###xml 531 535 531 535 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CCGG</italic>
###xml 541 549 541 549 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ESR2 AA </italic>
###xml 583 585 583 585 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 639 649 639 649 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ESR1 CCGG </italic>
###xml 654 665 654 665 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ESR2 AA-AG </italic>
###xml 724 734 722 732 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ESR1 TTAA </italic>
###xml 739 747 737 745 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ESR2 GG </italic>
###xml 776 778 772 774 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 793 798 789 794 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ESR1 </italic>
###xml 802 807 798 803 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ESR2 </italic>
###xml 946 948 942 944 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
The general characteristics of the study population on the basis of allelic variability for ESR1 and ESR2 loci are described in Table 1. According to [12], genotype distributions of these two loci were found to be in HW equilibrium (data not shown), suggesting that the enrolled subjects represented a homogeneous genetic background. No difference was evidenced in ESR1 and ESR2 loci for all considered variables, though a tendency to on increased Ht and a delayed menarche age were detected for ESR1 rs2234693 CC, rs9340799 GG or CCGG, and ESR2 AA genotypes than for the opposites (P > 0.05, data not shown). Moreover, the combination of ESR1 CCGG plus ESR2 AA-AG genotype was significantly taller (164.2 +/- 6.06 cm) than ESR1 TTAA plus ESR2 GG genotype (161.7 +/- 6.74 cm; P = 0.044). When ESR1 and ESR2 genotypes were evaluated alone or in combination, no significant correlation was observed with weight, BMI, heart rate and blood pressure (P > 0.05).
###end p 37
###begin p 38
###xml 25 30 25 30 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ESR1 </italic>
###xml 34 39 34 39 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ESR2 </italic>
###xml 65 70 <span type="species:ncbi:9606">women</span>
Genotype variability for ESR1 and ESR2 loci in the 570 Caucasian women enrolled in the BONTURNO study.
###end p 38
###begin p 39
###xml 149 154 149 154 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ESR1 </italic>
###xml 222 237 222 237 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ESR1 rs2234693 </italic>
###xml 260 269 260 269 <italic xmlns:xlink="http://www.w3.org/1999/xlink">rs9340799</italic>
###xml 350 352 348 350 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 362 364 360 362 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 378 379 376 377 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 415 422 413 420 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ESR1 CT</italic>
###xml 423 426 421 424 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TT </italic>
###xml 496 498 494 496 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 562 567 560 565 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ESR1 </italic>
###xml 582 584 580 582 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 606 621 604 619 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ESR2 rs4986938 </italic>
###xml 655 657 651 653 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 667 669 663 665 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 695 697 691 693 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 729 746 725 742 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ESR2 rs4986938 A </italic>
###xml 791 793 785 787 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 803 805 797 799 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 881 883 873 875 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 892 894 884 886 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 941 942 933 934 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 986 991 978 983 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ESR1 </italic>
###xml 995 1000 987 992 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ESR2 </italic>
###xml 1011 1013 1003 1005 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
Regarding family history of osteoporosis (FHO) and of hip fracture (FHF), no significative association was found with single or combined analysis of ESR1 polymorphisms. In subjects positive both for FHO and for FHF, the 3 ESR1 rs2234693 genotypes (but not the rs9340799) were differently distributed than in subjects with double negative FHO-FHF (chi2 = 10.957, P < 0.01; Table 2), with odds ratio (OR) of founding ESR1 CT-TT genotypes in double positive FHO-FHF being 1.836 (95% CI 0.860-3.919, P = 0.06). No significant association was detected combining both ESR1 polymorphisms (P > 0.05). Furthermore, ESR2 rs4986938 genotypes correlated with FHF (chi2 = 11.881, P < 0.01) but not with FHO (P > 0.05), as having at least one ESR2 rs4986938 A allele correlated both with positive FHF (chi2 = 11.550, P < 0.001; OR 2.387, 95% CI 1.432-3.977) and with double positive FHO-FHF (chi2 = 9.407, P < 0.005; OR 2.871, 95% CI 8.804-35.403) (Table 2). No association was detected co-analyzing ESR1 and ESR2 genotypes (P > 0.05).
###end p 39
###begin p 40
###xml 73 78 73 78 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ESR1 </italic>
###xml 82 87 82 87 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ESR2 </italic>
Family history of osteoporosis (FHO) and of hip fracture (FHF) regarding ESR1 and ESR2 genotypes.
###end p 40
###begin p 41
###xml 149 150 149 150 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
###xml 194 211 194 211 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ESR1 rs2234693 C </italic>
###xml 219 227 219 227 <italic xmlns:xlink="http://www.w3.org/1999/xlink">i.e. CC </italic>
###xml 231 234 231 234 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CT </italic>
###xml 289 290 287 288 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 324 325 320 321 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 332 335 328 331 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TT </italic>
###xml 387 388 381 382 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 390 392 384 386 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 429 430 421 422 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 432 434 424 426 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 554 555 544 545 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 589 590 577 578 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 595 613 583 601 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ESR2 rs4986938 AA </italic>
###xml 651 654 639 642 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GG </italic>
###xml 687 688 673 674 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 690 692 676 678 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 729 730 713 714 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 732 734 716 718 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 837 842 821 826 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ESR1 </italic>
###xml 846 851 830 835 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ESR2 </italic>
###xml 17 22 <span type="species:ncbi:9606">women</span>
The 570 enrolled women were divided in 3 age groups: from 20 to 30 yrs (class 1), from 31 to 40 yrs (class 2) and from 41 to 50 yrs (class 3) (Table 3). In class 1, subjects having at least one ESR1 rs2234693 C allele (i.e. CC and CT genotypes) presented lower LS-BMD (1.023 +/- 0.112 g/cm2) and TH-BMD (0.927 +/- 0.122 g/cm2) than TT genotypes, respectively (LS-BMD 1.077 +/- 0.131 g/cm2, P = 0.0083; TH-BMD 0.969 +/- 0.121 g/cm2, P = 0.0474). Similar but not significant trends were detected in classes 2 and 3. In class 3, TH-BMD (0.860 +/- 0.111 g/cm2) and FN-BMD (0.738 +/- 0.108 g/cm2) of ESR2 rs4986938 AA genotype were lower than the opposite GG ones (TH-BMD 0.923 +/- 0.130 g/cm2, P = 0.0227; FN-BMD 0.798 +/- 0.119 g/cm2, P = 0.0180). Regarding LS-, TH- or FN-BMD, no other signifivative differences were observed co-analyzing ESR1 and ESR2 loci.
###end p 41
###begin p 42
###xml 69 74 69 74 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ESR1 </italic>
###xml 78 83 78 83 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ESR2 </italic>
Mean age-class adjusted values (SD) of LS-, TH- and FN-BMD regarding ESR1 and ESR2 genotypes.
###end p 42
###begin p 43
###xml 209 210 209 210 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 288 293 288 293 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ESR1 </italic>
###xml 297 302 297 302 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ESR2 </italic>
###xml 308 310 308 310 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 355 360 355 360 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ESR1 </italic>
###xml 364 369 364 369 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ESR2 </italic>
###xml 471 473 471 473 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 72 77 <span type="species:ncbi:9606">women</span>
According to previously published data, oral contraceptive users and 18 women considered in perimenopausal phase for serum FSH levels >30 IU/mL were excluded from statistic analysis for bone turnover markers [9]. Age class-adjusted levels of serum OC, CTX and P1NP did not segregate with ESR1 and ESR2 loci (P > 0.05). Furthermore, no differences between ESR1 and ESR2 polymorphisms, were detected for serum age class-adjusted levels of calcium, phosphate and magnesium (P > 0.05).
###end p 43
###begin title 44
Discussion
###end title 44
###begin p 45
###xml 71 73 71 73 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 74 76 74 76 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 471 473 471 473 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 566 568 566 568 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 569 571 569 571 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 693 695 693 695 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 696 698 696 698 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 699 701 699 701 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 82 87 <span type="species:ncbi:9606">women</span>
Low BMD is a major risk factor for spine and proximal femur fractures [13,14]. In women, BMD in adulthood is largely determined by the amount of bone accumulated at the end of their skeletal growth (peak bone mass), their rate of bone loss after menopause when ovaries cease producing estrogens, and age-related bone loss. It has been well established with the study of twins, that peak bone mass is highly heritable with an estimated heritability between 0.50 and 0.80 [15]. Conversely, published data on the heritability of bone loss at menopause are conflicting [16-18]. Therefore, BMD is a trait that lends itself to studies designed to identify the genes underlying its normal variation [16,17,19].
###end p 45
###begin p 46
###xml 400 402 400 402 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 403 405 403 405 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 794 795 794 795 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 787 792 <span type="species:ncbi:9606">women</span>
The past decade has seen an important increase in the use of association studies with candidate genes for the genetic analysis of complex traits such as BMD and/or fracture risk. Many genes have been examined for their association with normal BMD variation, which yields an ever-expanding candidate gene list. However, this approach has been largely criticized because of discrepancy in the results [20,21], often related to the small size of the enrolled cohorts. Moreover, most of the studies focused on postmenopausal female populations. In this view, the main purpose of the present study was to evaluate allelic influence of target genes, such as estrogen receptors, on inherited skeletal traits in a large and homogeneous population-based cohort of premenopausal healthy Caucasian women [9].
###end p 46
###begin p 47
###xml 4 9 4 9 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ESR1 </italic>
###xml 13 17 13 17 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ESR2</italic>
###xml 208 210 208 210 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 277 282 277 282 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ESR1 </italic>
###xml 286 291 286 291 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ESR2 </italic>
###xml 306 307 306 307 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 308 310 308 310 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 311 313 311 313 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 348 350 348 350 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 455 460 455 460 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ESR1 </italic>
###xml 464 469 464 469 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ESR2 </italic>
###xml 551 553 551 553 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 570 575 570 575 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ESR2 </italic>
###xml 1011 1016 1011 1016 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ESR1 </italic>
###xml 1020 1025 1020 1025 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ESR2 </italic>
###xml 1120 1125 1120 1125 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ESR1 </italic>
###xml 1129 1134 1129 1134 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ESR2 </italic>
###xml 381 393 <span type="species:ncbi:9606">participants</span>
###xml 413 418 <span type="species:ncbi:9606">women</span>
###xml 658 663 <span type="species:ncbi:9606">women</span>
###xml 709 714 <span type="species:ncbi:9606">women</span>
###xml 741 746 <span type="species:ncbi:9606">human</span>
###xml 1087 1092 <span type="species:ncbi:9606">women</span>
For ESR1 and ESR2, two genes worldwide evaluated by independent research groups, the results obtained even if compelling for their involvement in BMD, osteoporosis, or fracture, are, however, not conclusive [22]. Confounding factors encompassed ethnic-specific distribution of ESR1 and ESR2 polymorphisms [8,23,24]. For example, in the SWAN study [23] which enrolled 693 Caucasian participants (366 premenopausal women), specific associations of BMD with ESR1 and ESR2 genotypes varied according to race/ethnicity. Furthermore, 4 independent studies [24] concluded that ESR2 locus could be involved in FN-BMD in Caucasians, LS-BMD in Japanese postmenopausal women, and LS- and FN-BMD in Chinese premenopausal women. In addition, most of the human studies of genetic association with BMD have been cross-sectional, and only very few studies examined the association of the genotypes to BMD change within specific age ranges. For all these reasons the present study was aiming to compare the results obtained for ESR1 and ESR2 to other data obtained in age-equivalent studies in Caucasian women, examining the relation of ESR1 and ESR2 genes' polymorphisms.
###end p 47
###begin p 48
###xml 25 30 25 30 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ESR2 </italic>
###xml 37 39 37 39 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 62 67 62 67 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ESR1 </italic>
###xml 197 205 197 205 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ESR1 px </italic>
###xml 257 259 257 259 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 266 271 266 271 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ESR1 </italic>
###xml 325 327 325 327 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 328 330 328 330 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 403 405 403 405 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 406 408 406 408 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 466 468 466 468 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 526 528 526 528 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 560 568 560 568 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ESR1 px </italic>
###xml 615 617 615 617 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 663 666 663 666 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pvu</italic>
###xml 669 671 669 671 <italic xmlns:xlink="http://www.w3.org/1999/xlink">T </italic>
###xml 675 678 675 678 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Xba</italic>
###xml 680 682 680 682 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A </italic>
###xml 717 725 717 725 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ESR1 px </italic>
###xml 790 792 790 792 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 943 945 943 945 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 995 1003 995 1003 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ESR1 Pvu</italic>
###xml 1006 1009 1006 1009 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Xba</italic>
###xml 1039 1041 1039 1041 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 1094 1102 1094 1102 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ESR1 px </italic>
###xml 1171 1173 1171 1173 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 1238 1240 1238 1240 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 1331 1339 1331 1339 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ESR1 px </italic>
###xml 1400 1408 1400 1408 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ESR1 px </italic>
###xml 1458 1460 1458 1460 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 1484 1491 1484 1491 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ESR1 CC</italic>
###xml 1493 1496 1493 1496 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GG </italic>
###xml 1499 1503 1499 1503 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CCGG</italic>
###xml 1509 1517 1509 1517 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ESR2 AA </italic>
###xml 1534 1544 1534 1544 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ESR1 CCGG </italic>
###xml 1549 1560 1549 1560 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ESR2 AA-AG </italic>
###xml 1634 1639 1634 1639 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ESR2 </italic>
###xml 1649 1654 1649 1654 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ESR1 </italic>
###xml 1680 1682 1680 1682 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 1727 1732 1727 1732 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ESR2 </italic>
###xml 1736 1741 1736 1741 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ESR1 </italic>
###xml 459 464 <span type="species:ncbi:9606">women</span>
###xml 508 513 <span type="species:ncbi:9606">women</span>
###xml 784 788 <span type="species:ncbi:9606">boys</span>
###xml 838 843 <span type="species:ncbi:9606">women</span>
###xml 862 867 <span type="species:ncbi:9606">women</span>
###xml 1308 1313 <span type="species:ncbi:9606">girls</span>
Differently than for the ESR2 locus [25], allelic variants of ESR1 gene were proposed to affect skeletal growth, through a genotype-dependent estrogen sensitivity at the growth cartilage, with the ESR1 px haplotype being less sensitive to estrogen effects [26]. The ESR1 haplotype effect was supported by functional studies [27,28] and by multiple association analysis documented for this gene variant [29-33]. For example, body Ht in pre- and postmenopausal women [29] and estradiol levels in premenopausal women were lower [30], with the number of copies of ESR1 px haplotype in their genotype. Lorentzon et al. [31] found an association between reduced Ht and PvuII T and XbaI A alleles, which corresponded to the ESR1 px haplotype. Although this study was performed in adolescent boys [31], it is in line with other findings in adult women. In 607 Caucasian women (aged 55-80 yrs) in whom vertebral fractures were excluded, Schuit et al. [29] observed significant association between Ht and ESR1 PvuII-XbaI haplotypes. In contrast to [32], a significant allele dose effect was observed for ESR1 px haplotype, corresponding to a 0.9-cm decrease in Ht per allele copy (P for trend = 0.02), extreme genotypes varied 1.8 cm. Boot et al. [33] partially confirmed this allele dose-effect to some extent, as in girls heterozygous for ESR1 px haplotype the Ht was higher than in those homozygous for the ESR1 px haplotype. In our series, higher Ht was slightly (P > 0.05) correlated with ESR1 CC, GG or CCGG, and ESR2 AA genotypes, while ESR1 CCGG plus ESR2 AA-AG genotype was significantly (2.5-cm) taller than the opposite genotype. As ESR2 modulates ESR1 transcriptional activity [34], this novel biological interaction between ESR2 and ESR1 genotypes is not surprising.
###end p 48
###begin p 49
###xml 66 68 66 68 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 194 202 194 202 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ESR1 px </italic>
###xml 222 224 222 224 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 333 341 333 341 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ESR1 XX </italic>
###xml 413 421 413 421 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ESR1 Pvu</italic>
###xml 438 440 438 440 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 477 479 477 479 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 546 561 546 561 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ESR1 rs2234693 </italic>
###xml 565 575 565 575 <italic xmlns:xlink="http://www.w3.org/1999/xlink">rs9340799 </italic>
###xml 95 100 <span type="species:ncbi:9606">women</span>
Family history is a major risk factor for osteoporotic fractures [35]. In white postmenopausal women, increased BMD-independent risk for vertebral (but not non-vertebral) fractures was found in ESR1 px haplotype carriers [26]. Moreover, the GENOMOS Consortium found a BMD-independent protective effect against vertebral fractures in ESR1 XX homozygous individuals, while no effects on fracture risk were seen for ESR1 PvuII polymorphism [22]. Similarly to the InCHIANTI study [36], we could not demonstrate any strong association between FHF and ESR1 rs2234693 and rs9340799 genotypes. However, our study might have had not enough power to detect any differences.
###end p 49
###begin p 50
###xml 12 17 12 17 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ESR2 </italic>
###xml 53 58 53 58 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ESR1 </italic>
###xml 136 138 136 138 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 155 170 155 170 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ESR2 rs4986938 </italic>
###xml 179 193 179 193 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ESR1 rs2234693</italic>
###xml 214 216 214 216 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 318 323 318 323 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ESR1 </italic>
###xml 373 388 373 388 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ESR2 rs4986938 </italic>
###xml 398 400 398 400 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 423 425 423 425 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
###xml 548 557 546 555 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UTR ESR2 </italic>
###xml 670 685 668 683 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ESR2 rs4986938 </italic>
###xml 763 768 761 766 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ESR2 </italic>
###xml 115 120 <span type="species:ncbi:9606">women</span>
###xml 266 271 <span type="species:ncbi:9606">women</span>
###xml 479 484 <span type="species:ncbi:9606">women</span>
Variants of ESR2 gene, alone and in interaction with ESR1 genotypes influenced the fracture risk in postmenopausal women. Moron et al. [37] suggested that ESR2 rs4986938 (but not ESR1 rs2234693) could have a role (P = 0.04) in osteoporosis in Spanish postmenopausal women. Furthermore, they detected a joint effect of ESR1 gene in osteoporosis modulating the penetrance of ESR2 rs4986938 genotype [37]. Rivadeneira et al. [38] showed for the first time that white postmenopausal women (>/= 55 yrs of age) who are homozygous for a common intron 2-3'UTR ESR2 haplotype allele have 40-80% increased risk of fragility and vertebral fracture. Interestingly, we also observed ESR2 rs4986938 genotypes significantly correlated with FHF risk but not with FHO, suggesting ESR2 variants may affect bone strength independently of BMD.
###end p 50
###begin p 51
###xml 44 46 44 46 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
###xml 86 94 86 94 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ESR1 Pvu</italic>
###xml 127 129 127 129 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 247 255 245 253 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ESR1 Xba</italic>
###xml 264 266 262 264 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
###xml 303 305 301 303 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B40">40</xref>
###xml 370 378 368 376 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ESR1 Pvu</italic>
###xml 385 388 383 386 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Xba</italic>
###xml 480 483 478 481 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Xba</italic>
###xml 579 581 577 579 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B41">41</xref>
###xml 697 702 695 700 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ESR1 </italic>
###xml 726 734 724 732 <italic xmlns:xlink="http://www.w3.org/1999/xlink">i.e. Pvu</italic>
###xml 741 744 739 742 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Xba</italic>
###xml 891 893 889 891 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 902 904 900 902 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 961 963 959 961 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 964 966 962 964 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
###xml 967 969 965 967 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B41">41</xref>
###xml 1025 1040 1023 1038 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ESR1 rs2234693 </italic>
###xml 1049 1058 1047 1056 <italic xmlns:xlink="http://www.w3.org/1999/xlink">rs9340799</italic>
###xml 178 183 <span type="species:ncbi:9606">women</span>
###xml 418 423 <span type="species:ncbi:9606">women</span>
###xml 496 501 <span type="species:ncbi:9606">women</span>
###xml 621 626 <span type="species:ncbi:9606">women</span>
According to our findings, McGuigan et al. [39] observed a modest association between ESR1 PvuII genotypes and BMD at the hip (P = 0.034) but not at the spine in 216 young Irish women (mean age 22.6 +/- 1.6 yrs), with no differences regarding the ESR1 XbaI locus [39]. On the other hand, Valero et al. [40] found no significant relations between FN- or LS-BMD with both ESR1 PvuII and XbaI loci in 194 older Caucasian women aged 22-45 yrs. Furthermore, a cross sectional study of XbaI and BMD in women who were premenopausal and perimenopausal, did not confirm this association [41]. Finally, in perimenopausal Caucasian women (older than 48.5 yrs) enrolled in the GENOMOS consortium, none of two ESR1 intron 1 polymorphisms (i.e. PvuII and XbaI loci) or derived haplotypes had any statistically significant effect on BMD, with estimated differences between genetic contrasts being 0.01 g/cm2 or less [22]. Collectively, our findings and the published studies [22,39-41] make possible to support a significant effects of the ESR1 rs2234693 (but not rs9340799) locus on the BMD mainly in the young adult next to her achievement of bone peak mass.
###end p 51
###begin p 52
###xml 52 57 52 57 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ESR2 </italic>
###xml 101 103 101 103 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 129 144 129 144 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ESR2 rs4986938 </italic>
###xml 262 264 260 262 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B42">42</xref>
###xml 302 317 300 315 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ESR2 rs4986938 </italic>
###xml 454 456 450 452 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 524 539 520 535 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ESR2 rs4986938 </italic>
###xml 619 634 615 630 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ESR1 rs2234693 </italic>
###xml 676 681 672 677 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ESR1 </italic>
###xml 685 690 681 686 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ESR2 </italic>
###xml 195 200 <span type="species:ncbi:9606">women</span>
###xml 421 426 <span type="species:ncbi:9606">women</span>
###xml 597 602 <span type="species:ncbi:9606">women</span>
Previous approaches have also suggested the role of ESR2 in BMD within different ethnic backgrounds [24]. No association between ESR2 rs4986938 with LS- or FN-BMD were detected in 1291 Caucasian women (from 192 families) aged 33.2 +/- 7.1 yrs (range 20-50 yrs) [42]. Similarly, no associations between ESR2 rs4986938 genotypes and Ht, LS-BMD and serum OC levels were detected in 147 healthy peri and postmenopausal Greek women (mean age 54 +/- 7.9 yrs) [25]. On the other hand, we detected significant BMD variations of the ESR2 rs4986938 genotypes only in the later age group (i.e. 41-50 yrs old women). Together with ESR1 rs2234693 data, this reinforces the hypothesis that ESR1 and ESR2 genes affect bone metabolism in precise and distinct age-sequential windows. Larger pre-planned analysis will be necessary to confirm our interpretation.
###end p 52
###begin p 53
###xml 121 126 121 126 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ESR1 </italic>
###xml 130 135 130 135 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ESR2 </italic>
###xml 655 657 655 657 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 867 869 867 869 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B43">43</xref>
###xml 716 722 <span type="species:ncbi:9606">humans</span>
###xml 1031 1037 <span type="species:ncbi:9606">humans</span>
In conclusion, taken together, our findings indicated that, although the effect size may be small, allelic variations in ESR1 and ESR2 genes are associated with various and different bone traits (e.g. Ht, BMD and FHF risk) in normal premenopausal Caucasian subject. Furthermore, multiple genotype interactions were detected that reinforced the polygenic and complex character of skeletal system. In some cases however, the mean pattern of bone trait values for a gene polymorphism with evidence of association was not in agreement with previously published studies. Therefore, even though family history of fragility fractures is one of the risk factors [35], we cannot recommend genetic testing for clinical use in humans to better identify population at risk for pathologic bone traits such as fragility fractures. However, as it has been shown for other diseases [43], extended panels of several polymorphic markers could be used in the future, in addition to traditional risk factors, to evaluate the skeletal disorder risk in humans.
###end p 53
###begin title 54
Competing interests
###end title 54
###begin p 55
All authors participating to the BONTURNO study, and then to the preparation of this manuscript, did not have competing interests regarding the present data.
###end p 55
###begin title 56
Authors' contributions
###end title 56
###begin p 57
Both FM carried out the molecular genetic studies, performed the statistical analysis and drafted the manuscript. LM participated in the sequence alignment. GB, SM, GL and LM carried out the subject enrolment and their clinical evaluation. AP, SS and DM participated in the design of the study and in the subject data collection. MLB conceived of the study, and participated in its design and coordination and helped to draft the manuscript. All authors read and approved the final manuscript.
###end p 57
###begin title 58
Acknowledgements
###end title 58
###begin p 59
The BONTURNO Study and the genetic research were supported by GlaxoSmithKline-Italia (Verona, Italy). All study contributors and their location (in alphabetical order) were: Silvano Adami (Verona), Maurizio Bevilacqua (Milano), Gerolamo Bianchi (Genova), Ottavio Bosello (Verona), Maria Luisa Brandi (Firenze), Francesco Cantatore (Foggia), Ombretta Di Munno (Pisa), Erio Fiore (Catania), Bruno Frediani (Siena), Giorgio Gandolini (Milano), Sandro Giannini (Padova), Vincenzo Lo Cascio (Verona), Giovanni Luisetto (Padova), Claudio Marcocci (Pisa), Salvatore Minisola (Roma), Maurizio Muratore (Lecce), Ranuccio Nuti (Siena), Sergio Ortolani (Milano), Gian Battista Rini (Palermo), Maurizio Rossini (Verona), Fabio Massimo Ulivieri (Milano).
###end p 59
###begin article-title 60
###xml 77 80 <span type="species:ncbi:9606">men</span>
###xml 85 90 <span type="species:ncbi:9606">women</span>
Attainment of peak bone mass at the lumbar spine, femoral neck and radius in men and women: relative contributions of bone size and volumetric bone mineral density
###end article-title 60
###begin article-title 61
The contribution of bone loss to postmenopausal osteoporosis
###end article-title 61
###begin article-title 62
A theoretical analysis of the relative influences of peak BMD, age-related bone loss and menopause on the development of osteoporosis
###end article-title 62
###begin article-title 63
Genetics of male osteoporosis
###end article-title 63
###begin article-title 64
Management of post-menopausal osteoporosis: something new on the horizon?
###end article-title 64
###begin article-title 65
Genetics of menopause-associated diseases
###end article-title 65
###begin article-title 66
Pharmacogenetics of bone treatments: the VDR and ERalpha gene story
###end article-title 66
###begin article-title 67
###xml 63 68 <span type="species:ncbi:9606">Women</span>
Determinants of Bone Turnover Markers in Healthy Premenopausal Women
###end article-title 67
###begin article-title 68
Standardization of bone mineral density at femoral neck, trochanter and Ward's triangle
###end article-title 68
###begin article-title 69
###xml 66 71 <span type="species:ncbi:9606">human</span>
###xml 173 178 <span type="species:ncbi:9606">women</span>
Evidence of a linkage disequilibrium between polymorphisms in the human estrogen receptor alpha gene and their relationship to bone mass variation in postmenopausal Italian women
###end article-title 69
###begin article-title 70
Long-term fracture prediction by bone mineral assessed at different skeletal sites
###end article-title 70
###begin article-title 71
Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures
###end article-title 71
###begin article-title 72
Genetic determinants of bone mass in adults. A twin study
###end article-title 72
###begin article-title 73
###xml 89 94 <span type="species:ncbi:9606">women</span>
Genetic and environmental influences on bone mineral density in pre- and post-menopausal women
###end article-title 73
###begin article-title 74
Genetic variation in bone mineral density and calcaneal ultrasound: a study of the influence of menopause using female twins
###end article-title 74
###begin article-title 75
Genetic control of susceptibility to osteoporosis
###end article-title 75
###begin article-title 76
Familial resemblance of bone mineral density (BMD) and calcaneal ultrasound attenuation: the BMD in mothers and daughters study
###end article-title 76
###begin article-title 77
Problems of reporting genetic associations with complex outcomes
###end article-title 77
###begin article-title 78
Candidate-gene approaches for studying complex genetic traits: practical considerations
###end article-title 78
###begin article-title 79
Differential genetic effects of ESR1 gene polymorphisms on osteoporosis outcomes
###end article-title 79
###begin article-title 80
The association of bone mineral density with estrogen receptor gene polymorphisms
###end article-title 80
###begin article-title 81
###xml 70 75 <span type="species:ncbi:9606">women</span>
###xml 80 83 <span type="species:ncbi:9606">men</span>
Estrogen receptor beta polymorphisms are associated with bone mass in women and men: the Framingham Study
###end article-title 81
###begin article-title 82
###xml 125 130 <span type="species:ncbi:9606">women</span>
Correlation of estrogen receptor beta gene polymorphisms with spinal bone mineral density in peri- and post-menopausal Greek women
###end article-title 82
###begin article-title 83
Association of 5' estrogen receptor alpha gene polymorphisms with bone mineral density, vertebral bone area and fracture risk
###end article-title 83
###begin article-title 84
Estrogen receptor alpha gene polymorphisms and risk of myocardial infarction
###end article-title 84
###begin article-title 85
Common estrogen receptor polymorphism augments effects of hormone replacement therapy on E-selectin but not C-reactive protein
###end article-title 85
###begin article-title 86
###xml 34 39 <span type="species:ncbi:9606">women</span>
Height in pre- and postmenopausal women is influenced by estrogen receptor alpha gene polymorphisms
###end article-title 86
###begin article-title 87
###xml 98 103 <span type="species:ncbi:9606">women</span>
Estrogen receptor alpha gene polymorphisms are associated with estradiol levels in postmenopausal women
###end article-title 87
###begin article-title 88
###xml 112 116 <span type="species:ncbi:9606">boys</span>
Estrogen receptor gene polymorphism, but not estradiol levels, is related to bone density in healthy adolescent boys: a cross-sectional and longitudinal study
###end article-title 88
###begin article-title 89
Estrogen receptor alpha gene polymorphisms are associated with changes in bone remodeling markers and treatment response to estrogen
###end article-title 89
###begin article-title 90
###xml 79 87 <span type="species:ncbi:9606">children</span>
Estrogen receptor alpha gene polymorphisms and bone mineral density in healthy children and young adults
###end article-title 90
###begin article-title 91
###xml 51 56 <span type="species:ncbi:9606">human</span>
The estrogen receptor beta-isoform (ERbeta) of the human estrogen receptor modulates ERalpha transcriptional activity and is a key regulator of the cellular response to estrogens and antiestrogens
###end article-title 91
###begin article-title 92
Genetic determinants of susceptibility to osteoporosis
###end article-title 92
###begin article-title 93
Relationship of volumetric bone mineral density and structural parameters with ERalpha gene polymorphisms
###end article-title 93
###begin article-title 94
###xml 72 77 <span type="species:ncbi:9606">women</span>
Multilocus analysis of estrogen-related genes in Spanish postmenopausal women suggests an interactive role of ESR1, ESR2 and NRIP1 genes in the pathogenesis of osteoporosis
###end article-title 94
###begin article-title 95
###xml 193 198 <span type="species:ncbi:9606">women</span>
Estrogen receptor beta (ESR2) polymorphisms in interaction with estrogen receptor alpha (ESR1) and insulin-like growth factor I (IGF1) variants influence the risk of fracture in postmenopausal women
###end article-title 95
###begin article-title 96
###xml 66 69 <span type="species:ncbi:9606">men</span>
###xml 74 79 <span type="species:ncbi:9606">women</span>
Genetic and environmental determinants of peak bone mass in young men and women
###end article-title 96
###begin article-title 97
Bone mass in young adults: relationship with gender, weight and genetic factors
###end article-title 97
###begin article-title 98
Estrogen receptor genotypes and their association with the 10-year changes in bone mineral density and osteocalcin concentrations
###end article-title 98
###begin article-title 99
###xml 110 113 <span type="species:ncbi:9606">men</span>
###xml 118 123 <span type="species:ncbi:9606">women</span>
Polymorphisms in the estrogen receptor beta (ESR2) gene are associated with bone mineral density in Caucasian men and women
###end article-title 99
###begin article-title 100
Common variation in three genes, including a noncoding variant in CFH, strongly influences risk of age-related macular degeneration
###end article-title 100

